16/07/2003
London, UK – 16 May, 2003: ReGen Therapeutics Plc (the ‘Company’) announces that on 15 July 2003 it received notification from Mr Colin Blackbourn that he is beneficially interested in 7,000,000 ordinary shares of the Company representing 3.1% of the current issued share capital of the Company.
For further information, please contact:
Andrew Marshall
Marshall Robinson Roe
Tel No 020 7489 2033